Abbott Laboratories (ABT) Plans $0.27 Quarterly Dividend
Abbott Laboratories (NYSE:ABT) declared a quarterly dividend on Friday, February 17th. Investors of record on Friday, April 14th will be paid a dividend of 0.265 per share by the healthcare product maker on Monday, May 15th. This represents a $1.06 dividend on an annualized basis and a yield of 2.40%.
Shares of Abbott Laboratories (NYSE:ABT) traded up 0.54% on Friday, reaching $44.44. The company had a trading volume of 4,937,789 shares. Abbott Laboratories has a 52-week low of $36.76 and a 52-week high of $45.79. The firm has a market capitalization of $65.43 billion, a PE ratio of 47.43 and a beta of 0.97. The company has a 50-day moving average price of $41.31 and a 200-day moving average price of $41.16.
Abbott Laboratories (NYSE:ABT) last issued its earnings results on Monday, February 6th. The healthcare product maker reported $0.65 EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.65. The business earned $5.33 billion during the quarter, compared to analysts’ expectations of $5.41 billion. Abbott Laboratories had a return on equity of 15.74% and a net margin of 6.71%. Abbott Laboratories’s revenue was up 2.8% compared to the same quarter last year. During the same quarter last year, the firm posted $0.62 earnings per share. Equities research analysts forecast that Abbott Laboratories will post $2.45 EPS for the current fiscal year.
Several analysts recently issued reports on ABT shares. Jefferies Group LLC reiterated a “buy” rating and set a $51.00 price objective on shares of Abbott Laboratories in a report on Friday. RBC Capital Markets cut their price objective on Abbott Laboratories from $48.00 to $46.00 and set an “outperform” rating for the company in a report on Thursday, January 26th. TheStreet lowered Abbott Laboratories from a “buy” rating to a “hold” rating in a report on Friday, December 2nd. Zacks Investment Research lowered Abbott Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday, January 11th. Finally, Royal Bank Of Canada cut their price objective on Abbott Laboratories from $48.00 to $46.00 and set an “outperform” rating for the company in a report on Thursday, January 26th. Five research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. Abbott Laboratories currently has a consensus rating of “Buy” and a consensus target price of $47.38.
“Abbott Laboratories (ABT) Plans $0.27 Quarterly Dividend” was originally published by Financial Market News and is the property of of Financial Market News. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of U.S. and international copyright laws. The original version of this piece can be accessed at http://www.financial-market-news.com/abbott-laboratories-abt-plans-0-27-quarterly-dividend/1321639/.
In related news, insider Heather L. Mason sold 35,700 shares of Abbott Laboratories stock in a transaction dated Tuesday, January 31st. The stock was sold at an average price of $40.77, for a total transaction of $1,455,489.00. Following the sale, the insider now directly owns 100,189 shares of the company’s stock, valued at $4,084,705.53. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Brian J. Blaser bought 15,580 shares of the firm’s stock in a transaction that occurred on Tuesday, December 20th. The shares were purchased at an average cost of $38.45 per share, for a total transaction of $599,051.00. Following the completion of the transaction, the insider now owns 129,782 shares of the company’s stock, valued at $4,990,117.90. The disclosure for this purchase can be found here. Insiders own 0.26% of the company’s stock.
Abbott Laboratories Company Profile
Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture and sale of a line of healthcare products. The Company operates in four business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products.
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.